Yutrepia is a drug owned by Liquidia Technologies Inc. It is protected by 5 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 05, 2037. Details of Yutrepia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11712442 | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | Active |
| US10898494 | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | Active |
| US11660304 | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | Active |
| US11744836 | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | Active |
| US11744835 | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | Active |
FDA has granted several exclusivities to Yutrepia. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Yutrepia, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Yutrepia.
Exclusivity Information
Yutrepia holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Yutrepia's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2028 |
US patents provide insights into the exclusivity only within the United States, but Yutrepia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Yutrepia's family patents as well as insights into ongoing legal events on those patents.
Yutrepia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Yutrepia's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 05, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Yutrepia Generics:
There are no approved generic versions for Yutrepia as of now.
About Yutrepia
Yutrepia is a drug owned by Liquidia Technologies Inc. Yutrepia uses Treprostinil Sodium as an active ingredient. Yutrepia was launched by Liquidia Tech in 2025.
Approval Date:
Yutrepia was approved by FDA for market use on 23 May, 2025.
Active Ingredient:
Yutrepia uses Treprostinil Sodium as the active ingredient. Check out other Drugs and Companies using Treprostinil Sodium ingredient
Dosage:
Yutrepia is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.0265MG BASE/INH | POWDER | Prescription | INHALATION |
| EQ 0.106MG BASE/INH | POWDER | Prescription | INHALATION |
| EQ 0.0795MG BASE/INH | POWDER | Prescription | INHALATION |
| EQ 0.053MG BASE/INH | POWDER | Prescription | INHALATION |